Capital Group Private Client Services Inc. Purchases 6,065 Shares of AbbVie Inc. $ABBV

Key Points

• Capital Group Private Client Services Inc. increased its AbbVie stake by 11.0% in the fourth quarter, buying 6,065 shares and lifting its total holdings to 61,160 shares worth about $13.97 million.
• Several other institutional investors also added to or initiated positions in AbbVie, and the company’s stock remains heavily held by institutions at 70.23% ownership.
• Wall Street sentiment is broadly positive, with analysts assigning AbbVie a Moderate Buy rating and an average price target of $253.43; recent news also highlighted regulatory wins for drugs like Elahere and Aquipta.

Capital Group Private Client Services Inc. boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 11.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 61,160 shares of the company's stock after acquiring an additional 6,065 shares during the period. Capital Group Private Client Services Inc.'s holdings in AbbVie were worth $13,974,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABBV. Chelsea Counsel Co. bought a new stake in AbbVie in the 3rd quarter worth $26,000. Westend Capital Management LLC bought a new stake in AbbVie in the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter worth $31,000. Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC grew its holdings in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price for the company. Bank of America raised shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price for the company in a research report on Thursday, April 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Finally, Piper Sandler raised their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an "overweight" rating in a research report on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average price target of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026's Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

AbbVie Price Performance

Shares of NYSE ABBV opened at $227.68 on Friday. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $244.81. The stock has a market cap of $402.27 billion, a P/E ratio of 112.16, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The firm has a 50-day moving average of $209.85 and a 200 day moving average of $219.36.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. During the same period last year, the company posted $2.46 EPS. AbbVie's revenue was up 12.4% on a year-over-year basis. Research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.